Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer

  • Technology appraisal guidance
  • TA801
  • Published: 
The committee meeting for this appraisal has been scheduled for 15 February 2022.